Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
The activity of VEGFR2 D1-7 was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml, corresponding to a specific activity of 100,000IU/mg.
Less than 0.1 ng/µg of protein.
Lyophilized from 25 mM MES pH 5.5, 100 mM NaCl
Reconstitute in sterile water to a concentration not less than 0.1 mg/ml. This solution can then be stored at 4°C for 2-7 days. For future use for future use; For long term storage it is recommended to add a carrier protein (0.1 % HSA or BSA).
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD.